5608 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Solit
    Solit
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Rosenberg
    Rosenberg
  7. Berger
    Berger
  8. Iyer
    Iyer
  9. Reuter
    Reuter
  10. Feldman
    Feldman

Groups

  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)
  7. Surgery (1000)
  8. Epidemiology and Biostatistics (864)
  9. Survivorship Research (773)
  10. Urology (769)
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 3 randomized study of cabozantinib (XL184) versus everolimus in subjects with clear cell renal cell carcinoma (METEOR)
    Meeting Abstract

    Choueiri, T. K.; Escudier, B. J.; Les, T. P.; Cella, D.; Ru, Q. C.; Scheffold, C.; Motzer, R. J.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • The Borealis-2 clinical trial: A randomized phase 2 study of OGX-427 (apatorsen) plus docetaxel versus docetaxel alone in relapsed/refractory metastatic urothelial cancer
    Meeting Abstract

    Choueiri, T. K.; Hahn, N. M.; Pai, S. K.; Alva, A. S.; Drelcer, R.; Starodub, A.; Sonpavde, G.; Hoffman-Censlts, J. H.; Plcus, J.; Baler, A. V.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Somatic copy number abnormalities (SCNAs) and mutations in PI3K/AKT pathway as prognostic factors for overall survival (OS) in platinum-treated locally advanced or metastatic urothelial tumors
    Meeting Abstract

    Bellmunt, J.; Werner, L.; Leow, J. J.; Mullane, S. A.; Riester, M.; Van Hummelen, P.; Rosenberg, J. E.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Q-TWiST analysis of patients with metastatic renal cell carcinoma (mRCC) randomized to pazopanib (PAZ) or sunitinib (SUN)
    Meeting Abstract

    Beaumont, J. L.; Diaz, J.; Deen, K. C.; McCann, L.; Powles, T.; Hackshaw, M. D.; Motzer, R. J.; Cella, D.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • A first-in-human study of pegylated recombinant human IL-10 (AM0010), daily administered for four months in selected advanced solid tumors
    Meeting Abstract

    Bauer, T. M.; Papadopoulos, K. P.; Autio, K. A.; Ott, P. A.; Whiteside, M.; Oft, M.; Infante, J. R.; Hod, F. S.; Wolchok, J. D.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Preliminary product parameter and safety results from NeuACT, a phase 2 randomized, open-label trial of DN24-02 in patients with surgically resected HER2+urothelial cancer at high risk for recurrence
    Meeting Abstract

    Bajorin, D. F.; Gomella, L. G.; Sharma, P.; Plimack, E. R.; O'Donnell, P. H.; Hoffman-Censits, J. H.; Flaig, T. W.; Quinn, D. I.; Campogan, D.; Haynes, H.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • A two-part phase 2 randomized study of dalantercept and axitinib versus placebo plus axitinib in advanced renal cell carcinoma: Results from the part 1 dose escalation cohorts
    Meeting Abstract

    Atkins, M. B.; Voss, M. H.; Plimack, E. R.; Rini, B. I.; Alter, R.; Dawson, N. A.; Beck, J. T.; Bhatt, R. S.; Pappas, K. M.; Wilson, D.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Primary, secondary, and quality-of-life endpoint results from PREVAIL, a phase 3 study of enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC)
    Meeting Abstract

    Armstrong, A. J.; Tombal, B.; Sternberg, C. N.; Higano, C. S.; Rathkopf, D. E.; Loriot, Y.; Saad, F.; Joshua, A. M.; de Bono, J. S.; Venner, P. M.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Amin, A.; Plimack, E. R.; Infante, J. R.; Ernstoff, M. S.; Rini, B. I.; McDermott, D. F.; Knox, J. J.; Pal, S. K.; Voss, M. H.; Sharma, P.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Stomatitis incidence and its relationship with efficacy: A meta-analysis of everolimus clinical studies
    Meeting Abstract

    Rugo, H. S.; Yao, J. C.; Pavel, M.; Ravaud, A.; Franz, D. N.; Taran, T.; Gallo, J.; Rouyrre, N.; Anak, O.; Motzer, R. J.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save